TY - JOUR
T1 - GM3 inhibits murine MBT-2 tumor invasion and growth
AU - Ohyama, Chikara
AU - Kawamura, Sadafumi
AU - Suzuki, Ken Ichi
AU - Numahata, Kenji
AU - Tokuyama, Satoru
AU - Ito, Akihiro
AU - Satoh, Makoto
AU - Saito, Seiichi
AU - Yoshikawa, Kazuyuki
AU - Hoshi, Senji
AU - Orikasa, Seiichi
PY - 1996/4
Y1 - 1996/4
N2 - GM3 has some important roles in cell-to-cell interaction and has proved to have an optimal concentration for fibronectin mediated cell adhesion. GM3 content in murine bladder tumor (MBT-2) assessed by thin-layer chromatography was similar to human invasive bladder tumor. From glycolipid composition also, MBT-2 is considered as an appropriate model for human invasive bladder tumor. Anti-tumor effect of locally administered GM3 on MBT-2 tumor was investigated. MBT-2 cells were injected subcutaneously into the right hind limb of CH3/HeSlc female mice on day 1. Tumor bearing mice were randomly placed on day 8 into GM3 treatment, GD3 treament, sialic acid treament and control groups. GM3 was administered between tumor and fascia at 10 μg in 0.1 ml, 1 μg in 0.1 ml from day 8 to day 20 every other day, 7 times in total. Control group was given 0.1 ml of saline. GD3 group was given 12.5 μg of GD3, and sialic acid group 2.5 μg of sialic acid. The relative growth rates of control group, GM3 1 μg group, GM3 10 μg group on day 22 were 139±74, 56±39, 22±14, respectively, and statistically significant among these three groups (Mann-Whitney's U test p<0.01). There were no significant difference between control and GD3 or sialic acid group. All of the 15 control mice had muscle invasion, however, of the 19 GM3 10 μg administered mice, only 4 had muscle invasion. The incidence of muscle invasion between these 2 groups was statistically significant in χ2 test (p<0.001). Locally administered GM3 inhibited both invasion and growth of MBT-2 tumor. This mechanism could be explained by an important role of GM3 in cell adhesion mediated by integrin and fibronectin interaction. These results may be applied to antiadhesion therapy of human invasive bladder tumor.
AB - GM3 has some important roles in cell-to-cell interaction and has proved to have an optimal concentration for fibronectin mediated cell adhesion. GM3 content in murine bladder tumor (MBT-2) assessed by thin-layer chromatography was similar to human invasive bladder tumor. From glycolipid composition also, MBT-2 is considered as an appropriate model for human invasive bladder tumor. Anti-tumor effect of locally administered GM3 on MBT-2 tumor was investigated. MBT-2 cells were injected subcutaneously into the right hind limb of CH3/HeSlc female mice on day 1. Tumor bearing mice were randomly placed on day 8 into GM3 treatment, GD3 treament, sialic acid treament and control groups. GM3 was administered between tumor and fascia at 10 μg in 0.1 ml, 1 μg in 0.1 ml from day 8 to day 20 every other day, 7 times in total. Control group was given 0.1 ml of saline. GD3 group was given 12.5 μg of GD3, and sialic acid group 2.5 μg of sialic acid. The relative growth rates of control group, GM3 1 μg group, GM3 10 μg group on day 22 were 139±74, 56±39, 22±14, respectively, and statistically significant among these three groups (Mann-Whitney's U test p<0.01). There were no significant difference between control and GD3 or sialic acid group. All of the 15 control mice had muscle invasion, however, of the 19 GM3 10 μg administered mice, only 4 had muscle invasion. The incidence of muscle invasion between these 2 groups was statistically significant in χ2 test (p<0.001). Locally administered GM3 inhibited both invasion and growth of MBT-2 tumor. This mechanism could be explained by an important role of GM3 in cell adhesion mediated by integrin and fibronectin interaction. These results may be applied to antiadhesion therapy of human invasive bladder tumor.
KW - Anti-tumor effect
KW - G
KW - MBT-2
UR - http://www.scopus.com/inward/record.url?scp=0029670429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029670429&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0029670429
SN - 1019-6439
VL - 8
SP - 809
EP - 813
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 4
ER -